Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

10:08 AM EDT, 09/23/2026 (MT Newswires) -- Coherus Oncology (CHRS) said Wednesday it has begun the process to sell remaining assets related to its former biosimilars business. The assets include patents and other intellectual property, royalties, cell lines, and related materials, the company said. The company said Oppenheimer will serve as its financial advisor for the sale. Shares of the company were down 3.2% in Wednesday trading. Price: 1.26, Change: -0.04, Percent Change: -3.15